ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers

Updated data for Blueprint's BLU-667 in RET-altered cancers presented Monday at the American Society of Clinical Oncology meeting in Chicago show that the compound could be competitive with fellow RET inhibitor LOXO-292 from Eli Lilly in RET-mutated NSCLC and thyroid cancers.